It’s here! Take a first look at He Named Me Malala a documentary about Nobel Peace Prize winner Malala Yousafzai’s life, story and personal journey as an education activist. Pledge to see the film only in theaters this October at http://bit.ly/1IlDIMg
Directed by acclaimed documentary filmmaker Davis Guggenheim (An Inconvenient Truth, Waiting for “Superman”), the film shows us how Malala, her father Zia and her family are committed to fighting for education worldwide.
Hulk Hogan has apologised for using racist language in a shocking tirade, which he has branded “unacceptable” as well as “inconsistent” with his own beliefs after he was sacked from WWE.
The former WWE star, who was fired from the wrestling company, issued a statement following the fall out on Friday.
In a statement issued shortly after one released by WWE, Hogan apologised for the racist tirade and admitted “there is no excuse” for his words.
He said: “Eight years ago I used offensive language during a conversation.
“It was unacceptable for me to have used that offensive language; there is no excuse for it and I apologise for having done it.
“This is not who I am. I believe very strongly that every person in the world is important and should not be treated differently based on race, gender, orientation, religious beliefs or otherwise.”
Hogan added: “I am disappointed with myself that I used language that is offensive and inconsistent with my own beliefs.”
The termination of his contracts comes after all references to him were removed from the official website, and rumours circulated that he had gone on a “racial tirade”.
In an official statement, WWE announced: “WWE terminated its contract with Terry Bollea (aka Hulk Hogan).
“WWE is committed to embracing and celebrating individuals from all backgrounds as demonstrated by the diversity of our employees, performers and fans worldwide.”
It is still not confirmed exactly why Hogan’s contract has been ended.
As well as his profile in the alumni section, all his merchandise has been pulled from the online store – certainly making it look like his time with the company has come to an end.
When searching for Hogan’s profile online and attempting to access it that way, an error message appears which reads: “You are not authorised to access this page.”
There are reports that the sudden end to their working relationship is the result of a video or audio of the star on a “racial tirade”, although renowned professional wrestling writer Dave Meltzer described it as “a rumour going round”.
An audio clip has surfaced on US website Radar Online online in which Hogan repeatedly uses the n-word during an interview discussing his early career and the use of the word on screen, although it appears this is from around 2012 and not the incident leading to the controversy.
He tweeted: “In the storm I release control,God and his Universe will sail me where he wants me to be,one love. HH (sic)”
Hogan himself is yet to comment on the reports, although he did post a cryptic message referring to a “storm”, and putting his faith in “God and his Universe”.
En savoir plus sur http://en.vogue.fr/fashion/a-bag-for-the-weekend/diaporama/moschinos-barbie-suitcase/21734#kqKDyDo01Y8W7G1D.99
Source: http://en.vogue.fr/fashion/a-bag-for-the-weekend/diaporama/moschinos-barbie-suitcase/21734/carrousel#le-sac-du-week-end-la-valise-barbie-de-moschino-1
First in a new class of injectable cholesterol-lowering drugs
July 24, 2015
The U.S. Food and Drug Administration today approved Praluent (alirocumab) injection, the first cholesterol-lowering treatment approved in a new class of drugs known as proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors.
Praluent is approved for use in addition to diet and maximally tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia (HeFH) or patients with clinical atherosclerotic cardiovascular disease such as heart attacks or strokes, who require additional lowering of LDL cholesterol.
HeFH is an inherited condition that causes high levels of low-density lipoprotein (LDL) cholesterol. A high level of LDL cholesterol (known as “bad” cholesterol) in the blood is linked to cardiovascular disease.Heart diseaseis the number one cause of death for Americans, both men and women. According to the Centers for Disease Control and Prevention, about610,000 people die of heart disease in the United States every year– that equals one in every four deaths.
“Praluent provides another treatment option for patients with HeFH or with known cardiovascular disease who have not been able to lower their LDL cholesterol enough on statins,” said John Jenkins, M.D., director of the Office of New Drugs, Center for Drug Evaluation and Research. “The FDA strongly supports continued work to provide new and innovative options for the treatment and prevention of cardiovascular disease.”
Praluent is an antibody that targets a specific protein, called PCSK9, which works by reducing the number of receptors on the liver that remove LDL cholesterol from the blood. By blocking PCSK9’s ability to work, more receptors are available to get rid of LDL cholesterol from the blood and, as a result, lower LDL cholesterol levels.
The efficacy and safety of Praluent were evaluated in five placebo-controlled trials, involving 2,476 participants exposed to Praluent. All participants had HeFH or were otherwise at high risk for heart attack or stroke, and were taking maximally tolerated doses of a statin, with or without other lipid‑modifying therapies. Participants taking Praluent had an average reduction in LDL cholesterol ranging from 36 to 59 percent, compared to placebo.
Multiple clinical trials have demonstrated that statins lower the risk of having a heart attack or stroke. A trial evaluating the effect of adding Praluent to statins on reducing cardiovascular risk is ongoing.
The most common side effects of Praluent include itching, swelling, pain, or bruising where injection is given, nasopharyngitis, and flu. Allergic reactions, such as hypersensitivity vasculitis (a skin rash usually appearing as purple-colored spots on the skin associated with inflammation of small blood vessels) and hypersensitivity reactions requiring hospitalization, have been reported with the use of Praluent. Patients should stop using Praluent and get medical help if they experience symptoms of a serious allergic reaction.
Praluent is marketed by Sanofi-Aventis U.S., based in Bridgewater, New Jersey, and Regeneron Pharmaceuticals Inc., based in Tarrytown, New York.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
SOURCE: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455883.htm
SunPeep 